Alto Neuroscience (ANRO) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ANRO Alto Neuroscience

Watchlist

12.755
+0.285+2.29%

Trading May 20 10:17 ET

342.91MMarket Cap-9448P/E (TTM)

Intraday

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Buy Rating for Alto Neuroscience: Promising Trials in MDD and Advances in CIAS Treatment
TipRanksMay 16 04:17 ET
TD Cowen Remains a Buy on Alto Neuroscience, Inc. (ANRO)
TipRanksMay 15 12:16 ET
Alto Neuroscience | 10-Q: Quarterly report
SEC announcementMay 14 16:38 ET · Announcements
Express News | Alto Neuroscience Inc: Qtrly Shr Loss $0.76
ReutersMay 14 16:28 ET
Express News | Alto Neuroscience Q1 2024 GAAP EPS $(0.76) Misses $(0.47) Estimate
BenzingaMay 14 16:22 ET
Alto Neuroscience 1Q Loss/Shr 76c >ANRO
Alto Neuroscience 1Q Loss/Shr 76c >ANRO
Dow JonesMay 14 16:11 ET

Comments

Jaguar8

Apr 23 07:36

$Alto Neuroscience(ANRO.US)$
NEWS
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
ALTO-101 demonstrated favorable pharmacokinetic and tolerability profile in Phase 1 study
Transdermal formulation provided significantly greater drug exposure with fewer adverse events
Proof-of-concept study for CIAS to start in the first half of 2024
Topline data expected in the second half of 2025
Achievement of target exposure with propri...

Moomoo AI

Feb 27 11:21

Investment firms see Alto Neuroscience's biomarker approach as a potential boost for clinical trials and patient outcomes. They predict a high stock risk/reward into 2H 2024/1H 2025 readouts, with a possible 100%-200% rise on positive data.